Takeda Pharmaceutical Co. Ltd. has generally been keen to do more in emerging markets like India, but the Japanese major has hitherto been somewhat tentative about a sharp ramp-up in the country. The $62bn planned acquisition of Shire PLC may now give it just that required impetus to push things forward, adding portfolio girth and momentum for future growth in a nation that is expected to see greater focus on healthcare as it tackles the growing burden of non-communicable diseases alongside infectious ailments. India also has an estimated 70 million patients with rare diseases.
[Sidebar#SC123062]





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
